NBIX News and Press, Neurocrine Biosciences Inc. From 01/08/23

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...

Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 3, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 41 st Annual J.P. Morgan Healthcare Conference at ...

Biotechs have been in a three-steps-forward, two-steps-back uptrend since early summer, and Neurocrine Biosciences (NBIX) continues to look like a leader in the space, both technically and fundamentally, suggests growth stock specialist Mike Cintolo, editor of Cabot Top Ten Trader. For further ...

Neurocrine Biosciences ( NASDAQ: NBIX ) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted its supplemental new drug application (sNDA) for valbenazine as a treatment for movement disorder associated with Huntington's disease. The FDA is set to decide on the sND...

Neurocrine Biosciences Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as a Treatment for Chorea Associated with Huntington Disease PR Newswire Prescription Drug User Fee Act (PDUFA) Target Action Date Set for August 20, 2023 SAN ...

Neurocrine Biosciences ( NASDAQ: NBIX ) announced that its investigational calcium channel blocker NBI-827104 did not meet the main goal in a Phase 2 trial in patients with the pediatric disorder, epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). The plac...

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep PR Newswire SAN DIEGO , Dec. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NB...

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022 PR Newswire SAN DIEGO , Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading n...

Summary Neurocrine announced another better-than-expected quarter for Ingrezza, as enhanced sales efforts are driving reacceleration in sales. The company will be announcing Phase II results from multiple programs over the next year, and while these are high-risk programs, success...

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting PR Newswire SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Neurocrin...